ADP-Glo: A bioluminescent and homogeneous adp monitoring assay for Kinases

Assay and Drug Development Technologies

Volumn 7, Issue 6, 2009, Pages 560-572

  Zegzouti, Hicham ^a   Zdanovskaia, Marina ^a   Hsiao, Kevin ^a   Goueli, Said A ^a,b  

^a PROMEGA CORPORATION   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; LIPID; LUCIFERASE; LUCIFERIN; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; REAGENT; STAUROSPORINE; SUGAR;

ARTICLE; BIOLUMINESCENCE; CELL LEVEL; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; ENZYME SUBSTRATE; SENSITIVITY ANALYSIS;

ADENOSINE DIPHOSPHATE; CHEMISTRY TECHNIQUES, ANALYTICAL; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; PHOSPHOTRANSFERASES; PROTEIN INTERACTION MAPPING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 76449097357     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0222     Document Type: Article

References (31)

1. Hunter T: Signaling-2000 and beyond. Cell 2000;100:113-127.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science 2002;298:1912-1934.
3. Zhang J, Yang PL, Gray NS: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
4. Johnson LN: Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys 2009;42:1-40.
5. Cohen P: Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;1:309-315.
6. Jia Y, Quinn CM, Kwak S, Talanian RV: Current in vitro kinase assay technologies: the quest for a universal format. Curr Drug Discov Technol 2008;5:59-69.
7. Ma H, Deacon S, Horiuchi K: The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Discov 2008;3:607-621.
8. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
9. Moore MJ, Adams JA, Taylor SS: Structural basis for peptide binding in protein kinase A. Role of glutamic acid 203 and tyrosine 204 in the peptide-positioning loop. J Biol Chem 2003;278:10613-10618.
10. Grant BD, Tsigelny I, Adams JA, Taylor SS: Examination of an active-site electrostatic node in the cAMP-dependent protein kinase catalytic subunit. Protein Sci 1996;5:1316-1324. (Pubitemid 26239439)
11. Kemp BE, Graves DJ, Benjamini E, Krebs EG: Role of multiple basic residues in determining the substrate specificity of cyclic AMP-dependent protein kinase. J Biol Chem 1977;252:4888-4894.
12. Lochner A, Moolman JA: The many faces of H89: a review. Cardiovasc Drug Rev 2006;24:261-274.
13. Meggio F, Donella Deana A, Ruzzene M, Brunati AM, Cesaro L, Guerra B, et al.: Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 1995;234:317-322.
14. Walsh DA, Glass DB: Utilization of the inhibitor protein of adenosine cyclic monophosphate-dependent protein kinase, and peptides derived from it, as tools to study adenosine cyclic monophosphate-mediated cellular processes. Meth Enzymol 1991;201:304-316.
15. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al.: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-18632.
16. Huss KL, Blonigen PE, Campbell RM: Development of a Transcreener kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J Biomol Screen 2007;12:578-584.
17. Lowery RG, Kleman-Leyer K: Transcreener: screening enzymes involved in covalent regulation. Expert Opin Ther Targets 2006;10:179-190.
18. Hong L, Quinn CM, Jia Y: Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology. Anal Biochem 2009;391:31-38.
19. Goueli SA, Hsiao K, Goueli BS: Assaying activity of individual protein kinases in crude tissue or cellular extracts. Meth Enzymol 2001;333:16-27.
20. Owicki JC: Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J Biomol Screen 2000;5:297-306.
21. Zaman GJ, Garritsen A, de Boer T, van Boeckel CA: Fluorescence assays for high-throughput screening of protein kinases. Comb Chem High Throughput Screen 2003;6:313-320.
22. Kupcho K, Somberg R, Bulleit B, Goueli SA: A homogeneous, nonradioactive high-throughput fluorogenic protein kinase assay. Anal Biochem 2003;317:210-217.
23. Charter NW, Kauffman L, Singh R, Eglen RM: A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5?-diphosphate accumulation. J Biomol Screen 2006;11:390-399.
24. Bazin H, Preaudat M, Trinquet E, Mathis G: Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptates as a tool for probing molecular interactions in biology. Spectrochim Acta A Mol Biomol Spectrosc 2001;57:2197-2211.
25. von Ahsen O, Schmidt A, Klotz M, Parczyk K: Assay concordance between SPA and TR-FRET in high-throughput screening. J Biomol Screen 2006;11:606-616.
26. Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, et al.: A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002;1:9-19.
27. Goueli SA, Hsiao K, Bulleit B: A homogenous, luminescent, high-throughput, versatile assay for a wide range of kinases. In: Handbook of Assay Development in Drug Discovery (Minor LK, ed.), pp. 99-114. Taylor & Francis Group, LLC. CRC, Boca Raton, FL, 2006.
28. Koresawa M, Okabe T: High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. Assay Drug Dev Technol 2004;2:153-160.
29. Baki A, Bielik A, Molnar L, Szendrei G, Keseru GM: A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors. Assay Drug Dev Technol 2007;5:75-83.
30. Auld DS, Zhang Y-Q, Southall NT, Rai G, Landsman M, Maclure J, et al.: A basis for reduced chemical library inhibition of firefl y luciferase obtained from directed evolution. J Med Chem 2009;52:1450-1458.
31. Tanega C, Shen M, Mott BT, Thomas CJ, MacArthur R, Inglese J, Auld DS: Comparison of bioluminescent kinase assays using substrate depletion and product formation. Assay Drug Dev Technol 2009;7:XX-XX